HIMS stock up 16% on Wednesday, continuing month-long gains. Novo Nordisk ends partnership, cites misleading marketing and safety concerns.

Telehealth platform Hims & Hers Health (NYSE:HIMS) shot to the top of stock charts yesterday as shares soared 16% high on no company news. While it is revolutionizing access to healthcare by ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Fangzhou has signed a MoU with Novo Nordisk to collaborate on the management of serious chronic diseases, including obesity and diabetes.

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

It isn't easy finding high-yield dividend growth stocks when the market is at an all-time high. Shares of Novo Nordisk and ...

More than a third of Hims & Hers public float — over 65 million shares, or about 33.5% — are being sold short, according to data from Benzinga Pro . This level of short interest is well above average ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Novo Nordisk announced it is cutting ties with telehealth giant Hims & Hers Health, pulling its blockbuster drug Wegovy from ...

If you suffered losses exceeding $50,000 in Hims between April 29, 2025 and June 22, 2025 and would like to discuss your ...

Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid ...

Shares of Hims & Hers Health (NYSE:HIMS) reached a session low on Friday after a bipartisan group of U.S. lawmakers urged the ...